MOXISYLYTE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H25NO3
Molecular Weight	279.3746
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C1=CC(OC(C)=O)=C(C)C=C1OCCN(C)C

InChI

InChIKey=VRYMTAVOXVTQEF-UHFFFAOYSA-N

InChI=1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3

HIDE SMILES / InChI

Molecular Formula	C16H25NO3
Molecular Weight	279.3746
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9711459
Curator's Comment: description was created based on several sources, including https://books.google.ru/books?id=S4GJio79XOUC&pg=PA97&lpg=PA97&dq=MOXISYLYTE+%09Withdrawal&source=bl&ots=dzBbL_E8c0&sig=r1pfUZ1LhFGihzzNswfGr7f38Mg&hl=ru&sa=X&ved=0ahUKEwjNlJeazZnOAhWJnBoKHZRoC3YQ6AEIVzAJ#v=onepage&q=MOXISYLYTE%20%09Withdrawal&f=false http://www.ncbi.nlm.nih.gov/pubmed/1475074

Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction, also was studied, that this drug may be useful to treat ocular disorders such as diabetic retinopathy. It is an alpha1-adrenergic antagonist. Was developed for self-injection therapy in France and marketed in several European countries as Icavex. In the spring 2005 the manufacturer of Icavex decided to withdraw this drug from Europe market, presumable due to its low market shares.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor alpha-1 169 Target ID: CHEMBL2094251 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10699651	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Erectile dysfunction 35 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9711459	Primary		Withdrawn	Unknown Approved Use Unknown
Diabetic retinopathy 17 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1475074	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Effects of thymoxamine and its metabolites on clonidine-induced hypotension and bradycardia in rats.	1982 Jul	6215903
Ergotamine-induced peripheral ischaemia reversed by oral thymoxamine hydrochloride.	1986 Jan	2936675
Alpha(1L)-, but not alpha(1H)-, adrenoceptor antagonist prevents allergic bronchoconstriction in guinea pigs in vivo.	2002 Sep 27	12323390
Electroacupuncture-induced pressor and chronotropic effects in anesthetized rats.	2006 Jan 30	16459151
Oral vasodilators for primary Raynaud's phenomenon.	2008 Apr 16	18425964

Patents

Sample Use Guides

In Vivo Use Guide

Intracavernous injection of moxisylyte at 10, 20 or 30 mg can induce an erection adequate for intercourse in most of the patients

Route of Administration: Other

In Vitro Use Guide

Moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue was investigated and compared with other alpha-adrenergic antagonists. Moxisylyte produced a concentration-dependent relaxation of a norepinephrine-induced (1 x 10(-5) M) contraction of the corpus cavernosum tissue. Pretreatment with 1 x 10(-6) M doses of moxisylyte reduced competitively the norepinephrine-induced contraction

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:08:12 GMT 2023` Edited by `admin` on `Fri Dec 15 15:08:12 GMT 2023`
Record UNII	PW8QYA7KI0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MOXISYLYTE

Official Name

English

MOXISYLYTE [MI]

Common Name

English

CARLYTENE

Brand Name

English

(2-(4-ACETOXY-2-ISOPROPYL-5-METHYLPHENOXY)ETHYL)DIMETHYLAMINE

Systematic Name

English

6-ACETOXYTHYMOL 2-(DIMETHYLAMINO)ETHYL ETHER

Common Name

English

THYMOXAMINE

Common Name

English

Moxisylyte [WHO-DD]

Common Name

English

moxisylyte [INN]

Common Name

English

Classification Tree Code System Code

WHO-ATC

G04BE06